ATE284898T1 - Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind - Google Patents
Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sindInfo
- Publication number
- ATE284898T1 ATE284898T1 AT00959292T AT00959292T ATE284898T1 AT E284898 T1 ATE284898 T1 AT E284898T1 AT 00959292 T AT00959292 T AT 00959292T AT 00959292 T AT00959292 T AT 00959292T AT E284898 T1 ATE284898 T1 AT E284898T1
- Authority
- AT
- Austria
- Prior art keywords
- synthetic
- expression
- human cells
- papillomavirus
- genes optimized
- Prior art date
Links
- 241001631646 Papillomaviridae Species 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 210000005260 human cell Anatomy 0.000 title 1
- 108020004705 Codon Proteins 0.000 abstract 2
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 abstract 1
- 208000009608 Papillomavirus Infections Diseases 0.000 abstract 1
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15072899P | 1999-08-25 | 1999-08-25 | |
US21014300P | 2000-06-07 | 2000-06-07 | |
PCT/US2000/022932 WO2001014416A2 (en) | 1999-08-25 | 2000-08-21 | Synthetic papillomavirus genes optimized for expression in human cells |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE284898T1 true ATE284898T1 (de) | 2005-01-15 |
Family
ID=26847958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00959292T ATE284898T1 (de) | 1999-08-25 | 2000-08-21 | Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1212358B1 (de) |
JP (1) | JP4799789B2 (de) |
AT (1) | ATE284898T1 (de) |
AU (1) | AU772611B2 (de) |
CA (1) | CA2381991A1 (de) |
DE (1) | DE60016765T2 (de) |
ES (1) | ES2233437T3 (de) |
PT (1) | PT1212358E (de) |
WO (1) | WO2001014416A2 (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
GB0017990D0 (en) | 2000-07-21 | 2000-09-13 | Glaxo Group Ltd | Papilloma virus sequences |
WO2002008435A1 (en) * | 2000-07-21 | 2002-01-31 | Glaxo Group Limited | Codon-optimized papilloma virus sequences |
US7022830B2 (en) * | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
DE10055545A1 (de) * | 2000-11-09 | 2002-07-25 | Deutsches Krebsforsch | Für Expression in Eukaryonten optimierte HPV 16-L1 und HPV 16-L2 kodierende DNA Sequenzen |
GB0105606D0 (en) * | 2001-03-07 | 2001-04-25 | Cantab Pharmaceuticals Res Ltd | Immunogens and vaccines and their preparation and use |
ES2284559T3 (es) | 2001-03-23 | 2007-11-16 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Genes y proteinas e6 y e7 modificados del vph utiles como vacuna. |
EP1604688B1 (de) * | 2001-06-05 | 2010-02-03 | CureVac GmbH | Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt |
DE10137102A1 (de) | 2001-07-30 | 2003-02-27 | Deutsches Krebsforsch | Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung |
GB0118532D0 (en) | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
CA2457890A1 (en) * | 2001-08-23 | 2003-03-06 | Merck & Co., Inc. | Vaccine using papillomavirus e proteins delivered by viral vector |
JP2005517639A (ja) | 2001-11-30 | 2005-06-16 | イシス イノベーション リミテッド | ワクチン |
FR2839072A1 (fr) * | 2002-04-24 | 2003-10-31 | Neovacs | Produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, composition immunogene contenant ledit produit d'expression et son procede de preparation |
CN100506999C (zh) * | 2003-03-24 | 2009-07-01 | 麦克公司 | Hpv31l1在酵母中的优化表达 |
MY140664A (en) | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
MY139500A (en) * | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
JP5148116B2 (ja) | 2004-02-11 | 2013-02-20 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | 癌胎児性抗原融合タンパク質及びその使用 |
PL1730175T3 (pl) | 2004-03-24 | 2010-09-30 | Merck Sharp & Dohme | Optymalizowana ekspresja L1 HPV 52 w drożdżach |
CN100392084C (zh) * | 2006-03-13 | 2008-06-04 | 曾毅 | 含密码子优化型hpv16l1基因的重组腺病毒 |
US8101342B2 (en) * | 2006-08-28 | 2012-01-24 | Sungkyunkwan University Foundation For Corporate Collaboration | DNA vaccine for treating or preventing cervical cancer comprising a gene encoding HPV protein |
CN101617052A (zh) | 2007-01-30 | 2009-12-30 | 特兰斯吉恩股份有限公司 | 用于免疫的乳头瘤病毒e2多肽 |
JP5474767B2 (ja) * | 2007-05-15 | 2014-04-16 | トランジェーヌ、ソシエテ、アノニム | 多重遺伝子発現のためのベクター |
EP2185195A2 (de) | 2007-08-16 | 2010-05-19 | Tripep Ab | Immunogen-plattform |
WO2012065034A1 (en) | 2010-11-12 | 2012-05-18 | Merck Sharp & Dohme Corp. | Enolase peptide conjugate vaccines against staphylococcus aureus |
EP3443982A1 (de) * | 2011-10-12 | 2019-02-20 | The Trustees of the University of Pennsylvania | Impfstoffe gegen humanes papillomavirus und verfahren zur verwendung davon |
EA034056B1 (ru) | 2013-03-12 | 2019-12-23 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Усовершенствованные вакцины против вируса папилломы человека и способы их применения |
ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
KR20230125200A (ko) * | 2020-11-24 | 2023-08-29 | 마 무초우 조 | 인간 유두종 바이러스에 대한 dna 백신 및 이를 사용하는 방법 |
CN113637690A (zh) * | 2021-08-18 | 2021-11-12 | 武汉华美生物工程有限公司 | 一种人乳头瘤病毒hpv16型e7活性蛋白的制备方法及应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5679509A (en) * | 1993-09-28 | 1997-10-21 | University Of New Mexico | Methods and a diagnostic aid for distinguishing a subset of HPV that is associated with an increased risk of developing cervical dysplasia and cervical cancer |
US5820868A (en) * | 1993-12-09 | 1998-10-13 | Veterinary Infectious Disease Organization | Recombinant protein production in bovine adenovirus expression vector system |
IL113817A (en) * | 1994-06-30 | 2001-03-19 | Merck & Co Inc | Polynucleotide for vaccination against the umbilical cord virus |
WO1996039178A1 (en) * | 1995-06-05 | 1996-12-12 | The Wistar Institute Of Anatomy And Biology | A replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
ES2274566T3 (es) * | 1997-02-07 | 2007-05-16 | MERCK & CO., INC. | Genes gag del vih sinteticos. |
US6228368B1 (en) * | 1997-10-06 | 2001-05-08 | Loyola University Of Chicago | Papilloma virus capsomere formulations and method of use |
-
2000
- 2000-08-21 WO PCT/US2000/022932 patent/WO2001014416A2/en active IP Right Grant
- 2000-08-21 DE DE60016765T patent/DE60016765T2/de not_active Revoked
- 2000-08-21 ES ES00959292T patent/ES2233437T3/es not_active Expired - Lifetime
- 2000-08-21 CA CA002381991A patent/CA2381991A1/en not_active Abandoned
- 2000-08-21 JP JP2001518745A patent/JP4799789B2/ja not_active Expired - Fee Related
- 2000-08-21 AT AT00959292T patent/ATE284898T1/de not_active IP Right Cessation
- 2000-08-21 EP EP00959292A patent/EP1212358B1/de not_active Revoked
- 2000-08-21 PT PT00959292T patent/PT1212358E/pt unknown
- 2000-08-21 AU AU70639/00A patent/AU772611B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
JP2003511010A (ja) | 2003-03-25 |
ES2233437T3 (es) | 2005-06-16 |
EP1212358A2 (de) | 2002-06-12 |
DE60016765D1 (de) | 2005-01-20 |
CA2381991A1 (en) | 2001-03-01 |
PT1212358E (pt) | 2005-04-29 |
WO2001014416A2 (en) | 2001-03-01 |
EP1212358B1 (de) | 2004-12-15 |
AU7063900A (en) | 2001-03-19 |
AU772611B2 (en) | 2004-05-06 |
JP4799789B2 (ja) | 2011-10-26 |
WO2001014416A3 (en) | 2001-12-06 |
DE60016765T2 (de) | 2005-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE284898T1 (de) | Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind | |
ATE342916T1 (de) | Synthetische hiv gag gene | |
HUP9901112A2 (hu) | Szintetikus HIV-gének | |
TW200519203A (en) | Optimized expression of HPV 58 L1 in yeast | |
AU3472299A (en) | Rna cancer vaccine and methods for its use | |
WO1997048370A3 (en) | Vaccines comprising synthetic genes | |
WO2000012127A3 (en) | Dna cancer vaccine and methods for its use | |
EA200500019A1 (ru) | Ксиланазы, кодирующие их нуклеиновые кислоты и способы их получения и применения | |
BRPI0408639B8 (pt) | molécula de ácido nucleico, vetor, célula hospedeira de levedura e método para produzir partículas semelhantes a vírus de hpv31 | |
MY140664A (en) | Optimized expression of hpv 45 l1 in yeast | |
SG153874A1 (en) | Neutralizing epitope-based growth enhancing vaccine | |
WO2003059381A3 (en) | Immunogenic preparations and vaccines on the basis of mrna | |
HUP0105379A2 (hu) | Lawsonia intracellularis elleni oltóanyag | |
ATE285239T1 (de) | Dna enthaltende impfstoffen | |
WO2001046225A3 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
TW200724679A (en) | Treatment of disease using an improved regulated expression system | |
ATE417106T1 (de) | Chlamydia antigene und deren korrespondierende dna fragmente und verwendungen davon | |
TW200510460A (en) | Antimicrobial polypeptides | |
NO20081541L (no) | Ny sjo-lus vaksine | |
ZA200602107B (en) | Piroplasmid vaccine | |
HUP0300813A2 (hu) | Gének, fehérjék és alkalmazásuk | |
WO2001046226A3 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
WO2013020133A3 (en) | Optimized antigens of pneumocystis and use thereof | |
ATE349539T1 (de) | In vivo stabilsierung von plasmiden | |
EA199900726A1 (ru) | Синтетические hiv gag гены |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1212358 Country of ref document: EP |
|
RZN | Patent revoked |